Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation

ConclusionsNo new safety or efficacy concerns were observed in this interim PMS analysis in Japanese patients with unresectable and metastatic melanoma withBRAF gene mutation who received dabrafenib and trametinib combination therapy.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research